|
|
Volumn 12, Issue 4, 2013, Pages 250-
|
|
Anticancer IGF1R classes take more knocks
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE;
BI 836845;
BYL 719;
DALOTUZUMAB;
DUSIGITUMAB;
GANITUMAB;
INSULIN RECEPTOR;
MAMMALIAN TARGET OF RAPAMYCIN;
METFORMIN;
MONOCLONAL ANTIBODY;
PHOSPHATIDYLINOSITOL 3 KINASE;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
RIDAFOROLIMUS;
SOMATOMEDIN;
SOMATOMEDIN C RECEPTOR;
TAMOXIFEN;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
BREAST CANCER;
BREAST TUMOR;
DRUG MECHANISM;
ESTROGEN RECEPTOR POSITIVE BREAST CANCER;
HUMAN;
MOLECULARLY TARGETED THERAPY;
NOTE;
PANCREAS CANCER;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
SIGNAL TRANSDUCTION;
SOLID TUMOR;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL MARKERS;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PYRAZOLES;
RECEPTOR, IGF TYPE 1;
TRIAZINES;
|
|
EID: 84875733362
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3992 Document Type: Note |
|
Times cited : (35)
|
|
References (0)
|
